Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study. Issue 9 (28th July 2020)

• Record Type: Journal Article
• Authors: Turunen, Antti; Valtola, Jaakko; Partanen, Anu; Ropponen, Antti; Kuittinen, Outi; Kuitunen, Hanne; Vasala, Kaija; Ågren, Lasse; Penttilä, Karri; Keskinen, Leena; Savolainen, Eeva-Riitta; Pyörälä, Marja; Kuittinen, Taru; Selander, Tuomas; Mäntymaa, Pentti; Pelkonen, Jukka; Jantunen, Esa; Varmavuo, Ville
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 9(2020)
• Page Start: 2082
• Page End: 2092
• Publication Date: 2020-07-28
• Subjects: Non-Hodgkin lymphoma -- autologous stem cell transplantation -- flow cytometry -- graft cellular composition -- outcome; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1762879
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Autologous stem cell transplantation (auto-SCT) is an established treatment option in patients with non-Hodgkin lymphoma (NHL). In this prospective multicenter study, the effect of infused blood graft cellular composition on post-transplant outcome was analyzed in 129 NHL patients. Higher graft CD34 + cell content (>2.5 × 10 6 /kg) correlated with better progression-free survival (PFS) ( p =.009) and overall survival (OS) ( p =.004). Higher graft CD34 + CD133 + CD38 – counts (>0.08 × 10 6 /kg) were also linked with better PFS ( p =.03) and OS ( p =.004), and these survival benefits retained in multivariate analyses. Higher infused CD3 + CD4 + cell count (>37 × 10 6 /kg) predicted better PFS ( p =.013) and OS ( p =.007) in multivariate analysis. Autograft cellular composition seems to impact outcome in NHL patients. These observations regarding composition of optimal graft in autologous setting should be validated in an independent patient series or in a randomized study.